PPARG and cancer: Subsequent studies indicated that PPARγ agonists, at concentrations of 1–10 μM, may induce growth inhibition in a variety of cancers, including cancers of breast, colon, and prostate (Kubota et al, 1998; Sarraf et al, 1998; Mehta et al, 2000).